October 2024 - Portal presented the poster "Addressing the Challenges of Highly Viscous Formulations Using a Needle-Free Technology" at the The PDA Universe of Pre-Filled Syringes and Injection Devices Conference in Arizona.
October 2024 - Portal recently shared its latest research at The PDA Universe of Pre-Filled Syringes and Injection Devices Conference in Arizona. The poster "Addressing the Challenges of Highly Viscous Formulations
Using a Needle-Free Technology" showed ex-vivo testing results which demonstrated PRIME Needle-Free injector can eject consistently and faster than a needle and syringe, while depositing the injectate at a similar depth in the subcutaneous space.
The ability for PRIME NF to eject high viscosity fluids consistently and rapidly could open the doors for new therapies as well as increase patient access to a more agreeable method of drug delivery. Having a needle-free system not only quells the common fear of needles but also boasts faster and more reliable injection times than a mechanical autoinjector. The findings of this study hint at the prospect of pushing beyond the constraints imposed by current needle-based injection devices.
Today Portal Instruments announced the signing of a multi-million-dollar development agreement with a leading biotech company to advance its large-volume, reusable autoinjector, PRIME NEXUS™, toward clinical readiness in Q1 2027.
June 30, 2021 - The National Transgender Discrimination Survey Report on Health and Health Care recorded at least 80% of transgender people have either taken gender-affirming hormone therapy (GAHT) or want to take GAHT at some point.¹
June 7, 2023 Cambridge, MA – Portal Instruments is pleased to announce that Bill Rich has joined its Board of Directors. Mr. Rich is a seasoned executive with vast leadership experience in biotechnology, medical devices, and pharmaceuticals.
Please fill out the details below and we will get back to you shortly.